NuGEN has revolutionized amplification and labeling technologies that enable life science researchers to mine genomic samples from extremely small, degraded, and hard-to-replace specimens.

As a partner in the discovery process, NuGEN brings solutions to top global pharmaceutical companies, academic institutions, and cutting edge biotechnology companies to meet their toughest challenges in clinical research, expression profiling, and biomarker and signature discovery.
NuGEN’s proprietary SPIA® technology is an elegant method for linear isothermal amplification of nucleic acids. This simple, high-fidelity approach to amplification enables global genomic analysis of limited and/or compromised biological samples, overcoming the challenges of sample quality and quantity with a high degree of sensitivity and accuracy.

Complex microarray platforms and various dissection technologies have evolved to enable analysis of highly homogenous biological samples. As a result, researchers have gained new opportunities to work with samples comprised of low numbers of cells such as laser captured microdissections, fine-needle aspirates, sorted cells, circulating tumor cells, embryonic structures, biopsies and Formalin-Fixed Paraffin-Embedded (FFPE) samples. Such sources often yield extremely small amounts of compromised RNA or DNA, adding to the difficulty in investigating these biological samples.

These challenges are met with NuGEN’s innovative technologies, which are at the core of a robust, sensitive, and easy to automate family of products and solutions that enable today’s discovery and clinical research projects